1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Fagron N.V.
  6. Company
    FAGR   BE0003874915

FAGRON N.V.

(FAGR)
  Report
Real-time Quote. Real-time Euronext Bruxelles - 05/19 11:35:02 am
16.16 EUR   -1.10%
05/16FAGRON N.V. : Ex-dividend day for final dividend
FA
05/09Fagron shareholders approve all voting items AGM and EGM
GL
05/09Fagron NV Approves Dividend for the Fiscal Year 2021, Payable on 18 May 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Fagron N.V.
Fagron N.V. specializes in the development, marketing and distribution of healthcare products and services intended for healthcare professionals and institutions. The group ensures the sale of pharmaceutical formulas and raw materials, provides third-party pharmaceutical compounding services to pharmacists and hospitals, etc.

Number of employees : 2 846 people.
Sales per Business
20202021Delta
Fagron EMEA267.3848.1%255.1044.5% -4.59%
Fagron North America159.5328.7%177.6331% +11.34%
Fagron Latin America129.0623.2%141.0824.6% +9.31%
EUR in Million
Sales per region
20202021Delta
EMEA267.3848.1%255.1044.5% -4.59%
North America159.5328.7%177.6331% +11.34%
Latin America129.0623.2%141.0824.6% +9.31%
EUR in Million
Managers
Name Title Age Since
Rafael Padilla Papaceit Chief Executive Officer & Executive Director 43 2018
Karin de Jong Chief Financial Officer & Executive Director 42 2016
Karen Berg Global Manager-Investor Relations - -
Constantijn Roderick van Rietschoten Chief Corporate Affairs Officer 52 2016
Marc van der Aa Global Director-Digital - -
Johan Verlinden Director-Global Legal Affairs - -
Céline Caveye Global Director-Human Resources - 2011
Members of the board
Name Title Age Since
Koen Hoffman Chairman 53 2017
Giulia van Waeyenberge Independent Director 40 -
Hein Valere Maria Deprez Independent Director 60 -
Robert J. W. ten Hoedt Independent Non-Executive Director 61 -
Karin de Jong Chief Financial Officer & Executive Director 42 2016
Michael Schenck Non-Executive Director 39 -
Marc. A. A. A. L Coucke Non-Executive Director 57 2016
Rafael Padilla Papaceit Chief Executive Officer & Executive Director 43 2018
Shareholders
NameEquities%
NN Investment Partners BV 11,605,000 15.9%
Marc. A. A. A. L Coucke 3,641,933 4.99%
Kabouter Management LLC 3,569,500 4.89%
Mawer Investment Management Ltd. 2,986,368 4.09%
Templeton Investment Counsel LLC 2,188,281 3.00%
Norges Bank Investment Management 2,142,679 2.94%
Capital Research & Management Co. (World Investors) 2,126,554 2.91%
Fidelity Management & Research Co. LLC 1,911,700 2.62%
The Vanguard Group, Inc. 1,625,453 2.23%
Candriam Belgium SA 1,101,818 1.51%
Holdings
NameEquities%Valuation
FAGRON N.V. (FAGR) 103,627 0.14% 1,949,199 USD
Markets and indexes
- Compartiment A
- AMX / BEL Mid, Next 150, PEA
Stock Exchange Codes
- Bloomberg Code :  
- Reuters Code :  FAGR.BR
- Datastream Code :  
Company contact information
Fagron N.V.
Venecoweg 20A
BE-9810 Nazareth, Oost-Vlaanderen

Phone : +32 88 33 11 288
Fax : +32 88 33 11 210
web site : https://investors.fagron.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Fagron N.V.
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
FAGRON N.V.10.41%1 249
JOHNSON & JOHNSON2.59%461 811
PFIZER, INC.-14.65%282 789
ABBVIE INC.12.58%269 361
ELI LILLY AND COMPANY6.87%265 718
ROCHE HOLDING AG-15.26%264 329
NOVO NORDISK A/S1.07%238 091
MERCK & CO., INC.20.17%232 903
ASTRAZENECA PLC18.05%196 890
NOVARTIS AG8.37%191 223
BRISTOL-MYERS SQUIBB COMPANY23.53%163 981
SANOFI13.93%132 243
AMGEN INC.8.44%130 323
GLAXOSMITHKLINE PLC10.18%111 134
BAYER AG35.74%65 777
DAIICHI SANKYO CO., LTD.13.68%49 715
CHUGAI PHARMACEUTICAL CO., LTD-2.84%46 551
TAKEDA PHARMACEUTICAL COMPANY LIMITED17.63%44 429
ASTELLAS PHARMA INC.6.50%27 985
JIANGSU HENGRUI MEDICINE CO., LTD.-42.32%27 750
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD-33.03%26 513